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Background: Screening, brief intervention, and referral to treatment (SBIRT) approaches to reducing hazardous
alcohol and illicit drug use have been assessed in a variety of health care settings, including primary care, trauma
centers, and emergency departments. A major methodological concern in these trials, however, is “assessment
reactivity,” the hypothesized impact of intensive research assessments to reduce alcohol and drug use and thus
mask the purported efficacy of the interventions under scrutiny. Thus, it has been recommended that prospective
research designs take assessment reactivity into account. The present article describes the design of the National
Institute on Drug Abuse Clinical Trials Network protocol, Screening, Motivational Assessment, Referral, and
Treatment in Emergency Departments (SMART-ED), which addresses the potential bias of assessment reactivity.
Methods/design: The protocol employs a 3-arm design. Following an initial brief screening, individuals identified
as positive cases are consented, asked to provide demographic and locator information, and randomly assigned to
one of the three conditions: minimal screening only, screening + assessment, or screening + assessment + brief
intervention. In a two-stage process, the randomization procedure first reveals whether or not the participant will
be in the minimal-screening-only condition. Participants in the other two groups receive a more extensive baseline
assessment before it is revealed whether they have been randomized to also receive a brief intervention.
Comparing the screening only and screening + assessment conditions will allow determination of the incremental
effect of assessment reactivity.
Discussion: Assessment reactivity is a potential source of bias that may reduce and/or lead to an underestimation
of the purported effectiveness of brief interventions. From a methodological perspective, it needs to be accounted
for in research designs. The SMART-ED design offers an approach to minimize assessment reactivity as a potential
source of bias. Elucidating the role of assessment reactivity may offer insights into the mechanisms underlying
SBIRT as well as suggest clinical options incorporating assessment reactivity as a treatment adjunct.
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Since the publication of the Institute of Medicine’s re-
port on broadening the base of treatment for alcohol
problems [1], there has been a marked expansion in
efforts to identify individuals with hazardous or harm-
ful alcohol use, provide a brief intervention (BI) when
indicated, and refer those with more serious levels of
alcohol dependence for specialty substance abuse
treatment. This process, known as screening, brief
intervention, and referral to treatment (SBIRT), has
been expanded more recently to also screen for illicit
drugs, tobacco, and prescription medications [2,3]. It
has also been implemented in a variety of health care
settings where the prevalence of alcohol and drug
misuse are thought to be relatively high. These have
included primary care, trauma center, and emergency
department (ED) settings [2,4,5].
The interventions delivered in these settings to indivi-
duals who screen positive for hazardous or harmful alco-
hol or drug use are often quite brief, sometimes as short
as 15–20 minutes. These approaches are typically based
on the principles of motivational interviewing [6-8], with
feedback provided about the individual’s pattern of use
and consequences derived from screening questionnaires
or interviews. In clinical trials evaluating the efficacy of
such interventions, extensive assessments are also con-
ducted to elicit information characterizing the patient
sample. These assessments measure substance-related
and other variables that potentially moderate or mediate
the effects of treatment.
Increasing concerns have been raised in SBIRT clinical
trials regarding the potential impact of such assessments.
The intensive assessments, relative to the brevity of the
SBIRT intervention being delivered, have raised con-
cerns that the treatment outcome may be contaminated
by “assessment reactivity.” Assessment reactivity is the
process by which increasing an individual’s awareness of
potential problem areas by targeted and extensive assess-
ment may, in and of itself, initiate behavior change in
the absence of even a minimal intervention. Thus, it is
thought that the extensive assessment may have a posi-
tive therapeutic effect and contribute to the change
process [9]. While this may be beneficial from a clinical
perspective, assessment reactivity may reduce the differ-
ence between the active intervention effect relative to
the “inactive” control condition, thus concealing the
therapeutic benefit of the active intervention [10-14].
This may have contributed to the absence of a signifi-
cant difference between the intervention and “assess-
ment only” comparison conditions in some SBIRT trials
and led to an underestimation of the actual beneficial
effects of BI [15].
Issues of assessment reactivity were initially noted in
regard to the effects of repeated post-treatment follow-up assessments in longitudinal evaluations of alcohol
treatment interventions [16-18]. A randomized study
that varied both the frequency and intensity/comprehen-
siveness of post-treatment assessments, for example,
found the poorest drinking outcomes among patients in
the infrequent/low comprehensive assessment condition
[17]. These findings highlighted the clinical influence of
the assessment process on outcomes, and the authors
also noted the lack of previous methodological designs
to control or account for possible assessment reactivity.
Subsequent attention shifted from post-treatment fol-
low-up assessment to the potential impact of assess-
ments that take place prior to the initiation of treatment
in clinical trials [19,20]. These studies found that reduc-
tions in drinking/drug use occurred between an initial
screening, subsequent intake assessment, and the first
therapy session. Further, these screening/post-assess-
ment/pretreatment reductions predicted better treat-
ment outcomes. As an example, Epstein and colleagues
[19] found significant reductions in percentage of drinking
days after each of the following events: a brief 10-minute
telephone screening, a 90-minute clinical screening, and a
3–4 hour baseline research interview. However, there were
no changes from baseline to the day before treatment or
from the day before treatment to the end of the first week
of treatment. Thus, the primary change in drinking behav-
ior occurred prior to treatment initiation. While it could
be argued that the observed changes reflected regression
toward the mean [21], the increased attention to drinking
may initiate a change process and may reflect an active
therapeutic benefit of assessment [9,22]. Randomized
experimental evaluations of the effects of assessment on
measures of alcohol consumption among heavy-drinking
college students involved in BIs have similarly found a
reactivity effect [10,12,14], supporting the view that an ac-
tive therapeutic process is at play rather than regression to
the mean.
In contrast, studies in EDs targeting alcohol use
[23,24] and marijuana [25] have not found an assess-
ment reactivity effect. As an example, ED patients
identified as having hazardous drinking patterns were
randomly assigned to a screen-only, an assessment-
only, or an assessment + intervention condition [23].
Drinking outcomes at a 12-month follow-up indicated
that patients in both the screen-only and assessment
+ intervention conditions had greater, but nonsignifi-
cant, improvements compared with those in the
assessment-only condition. In a study with a similar
design, reductions in drinking-related outcomes were
found at a 12-month follow-up among individuals
identified as hazardous drinkers in the ED [24]. There
were no differences, however, between patients who
had been randomized to a 10–15 minute BI, a screen
+ assessment condition, or a screen-only group.
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been too few high-quality, appropriately designed stud-
ies to allow any firm conclusions about the existence of
assessment reactivity bias [11]. Based on these concerns,
it has been recommended that researchers consider
methodological approaches to identify, quantify, and
minimize the potential confounding and biasing effects
of assessment reactivity in any analyses targeting treat-
ment outcomes [11,13,15,20]. Most prior studies of
SBIRT, including those in EDs, have not done so. As
shown in Figure 1, most prior studies have compared a
screen + assessment condition with a screen + assess-
ment + intervention condition. Taking into account the
above recommendations, more recent approaches have
begun to include a screen-only condition that excludes
the intensive assessment component, in addition to the
other two conditions [23-25]. Such a design allows one
to disaggregate the impact of assessment from the com-
bined effect of assessment plus BI. Without the inclu-
sion of a “no assessment” or “minimal assessment”
control group, it is not possible to determine how much
the assessment contributed to outcome, or, in the case




These concerns were taken into consideration in the de-
sign of the NIDA Clinical Trials Network’s protocol,
Screening, Motivational Assessment, Referral, and Treat-
ment in Emergency Departments (SMART-ED) [26].
The study, which is being conducted in six emergency
departments across the US, is evaluating the efficacy of a
motivational interviewing-based BI delivered in the ED
setting, targeting individuals who screen positive for
using/abusing illicit drugs or prescription medications.Prior and More Recent E
SBIRT D










Figure 1 Prior and more recent emergency-department SBIRT designAll study materials and procedures have been reviewed
and approved by the appropriate Institutional Review
Boards (IRBs) of participating universities and affiliated
EDs. The trial will be conducted in compliance with
protocol, International Conference on Harmonisation
Good Clinical Practice guidelines, and applicable regula-
tory requirements. An independent Data and Safety
Monitoring Board oversees the study.
In order to assess the independent contributions of as-
sessment and the BI to outcomes in the study population,
a three-arm design was adopted. The three treatment
groups are (1) a minimal screen-only condition (MSO) in
which participants receive as little interaction as possible
and do not complete an intensive baseline assessment; (2)
screening, assessment, and (if indicated or requested)
referral to treatment (SAR); and (3) screening, assessment,
and (if indicated or requested) referral, plus BI lasting up
to 30 minutes in the ED followed by two telephone
booster intervention sessions within 1–4 weeks following
the ED visit (BI-B). Figure 2 presents an overview of this
design.
Primary hypotheses
There are three primary hypotheses: (1) Participants ran-
domized to BI-B will have fewer days of use of the
patient-defined primary problem substance during the
30 days prior to the 3-month assessment relative to par-
ticipants randomized to MSO; (2) participants rando-
mized to BI-B will have fewer days of use relative to
participants randomized to SAR; and (3) participants
randomized to SAR will have fewer days of use relative
to participants randomized to MSO.
The study also has a number of secondary objectives:
(1) To evaluate the effect of BI-B relative to SAR on sub-
stance abuse treatment engagement among those parti-
cipants who are referred to treatment; (2) to evaluate themergency Department 
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Figure 2 SMART-ED design overview.
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health-care utilization; (3) to evaluate several putative
predictors of outcome (patient demographics, substance
use severity at baseline, primary substance of abuse,
motivation, therapeutic alliance, perceived substance-
relatedness of ED visit, and psychiatric comorbidity) in
terms of both main effect and interaction with treatment
assignment; and (4) among participants assigned to
BI-B, to evaluate dose–response to the number of
booster sessions received.
Study population: Inclusion/exclusion criteria
To be included in the trial, individuals need to meet the
following criteria: (1) registration as patient in the ED
during study screening hours; (2) positive screen (≥3)
on the 10-item Drug Abuse Screening Test (DAST-10)
for problematic use of a nonalcohol, non-nicotine drug;
(3) at least one day of problematic drug use (excluding
alcohol and nicotine) in the past 30 days; (4) age 18 years
or older; (5) adequate English proficiency and literacy;
(6) ability to provide informed consent; and (7) access
to phone (for booster sessions). Individuals are excluded
from consideration if they meet any of the following
criteria: (1) Inability to participate due to emergency
treatment; (2) significant impairment of cognition or
judgment rendering the person incapable of informed
consent (e.g., traumatic brain injury, delirium, intoxica-
tion); (3) status as a prisoner or in police custody at the
time of treatment; (4) current engagement in addiction
treatment; (5) residence more than 50 miles from the
location of follow-up visits; (6) inability to provide suffi-
cient contact information (e.g., at least 2 reliable loca-
tors); and (7) prior participation in the current study.
Emergency department patients who are subsequently
hospitalized may differ from other ED patients in ways
that could affect outcome and response to treatment.For example, they would likely have more severe medical
conditions, which could affect motivation to change, and
may have greater exposure to treatment and referral
while in the hospital. Since there is no reliable way to
know which patients will be hospitalized at the time of
randomization, hospitalized patients will be kept in the
study. The ED logs will be reviewed to identify all parti-
cipants who are ultimately hospitalized as a result of
their ED visit. Secondary analyses will explore whether
such patients differ from nonhospitalized participants in
substance use outcome or treatment response.
Characteristics of participating emergency departments
To be included as potential sites for this trial, EDs
should have a large volume of patients who use drugs
and that represent the US population in aggregate, have
prior research experience, and not currently be routinely
conducting SBIRT targeting drug users. Further, they
should be able to present a convincing plan for patient
flow and use of space, have (or are able to hire) appro-
priate staff to conduct the study, have a sufficient refer-
ral network for patients needing specialty addiction
treatment, and have an ED physician who can serve as
protocol PI (or otherwise be actively involved in the
protocol). From a pool of 17 EDs that responded to an
initial site-survey request, and following review of the
above criteria and subsequent site visits to a smaller sub-
set of potential sites, six EDs were selected to participate
in the trial.
Primary and secondary outcome measures
The primary outcome for the study is the number of
days of use of the patient-defined primary problem drug,
assessed for the 30-day period preceding the 3-month
post-intervention follow-up, as assessed by the Timeline
Followback (TLFB) [27,28].
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included: (1) number of days of primary problem sub-
stance use during the 30 days preceding the 6- and 12-
month postintervention follow-ups; (2) days of abstin-
ence from all drug use during the 30 days preceding the
3-, 6-, and 12-month postintervention follow-ups; (3)
days of heavy drinking in the past 30 days at 3, 6, and
12 months; (4) quantity of use (dollar value, number of
times used) for the primary drug at 3, 6, and 12 months
from baseline; (5) change in days of use of the primary
drug between baseline and follow-up at 3, 6, and
12 months (only for the SAR and BI-B groups that com-
pleted the TLFB at baseline); (5) relative change in hair-
sample drug screen results for the primary drug and also
for any drug of abuse from baseline to 3, 6, and 12 months
postintervention; (6) consequences of drug use (based on
the NIDA-Modified Alcohol, Smoking and Substance In-
volvement Screening Test (NM-ASSIST) [29]; (7) partici-
pation in addiction treatment in the past 30 days at 3, 6,
and 12 months postintervention among SAR and BI-B
participants with probable dependence who are referred
for treatment (assessed with the Treatment Services Re-
view [TSR]) [30]; and (8) health-care utilization (num-
ber of ED visits, number of hospital days, and number
of outpatient visits) in the past 30 days at 3, 6, and
12 months based on TSR results.
Screening of potential participants
During defined recruitment hours, Research Assistants
(RAs) will identify possibly eligible patients seen in the
ED and will approach them about their willingness to
participate in anonymous screening to determine the
representativeness of the study sample. Participants will
provide verbal (not signed) consent using a brief IRB-
approved script for the anonymous collection of screen-
ing data, which includes age, gender, and reason for ED
visit. The RA will attempt to screen all ED patients until
recruitment hours have ended or the maximum recruit-
ment for the week is achieved (no more than 12 partici-
pants randomized per week per site). Refusals and
inability to participate (e.g., unavailable due to emer-
gency medical treatment, left without being seen) will
be recorded.
Study staff will time their involvement with patients to
minimize interference with medical treatment. Depend-
ing on level of acuity, some patients will be approached
prior to the initial evaluation by a physician, and some
after. Patients who show signs of intoxication (e.g., som-
nolence, slurring of speech) will not be screened unless
these signs resolve. Screening data will be collected by
research personnel and by participant self-report using
direct entry into tablet computers to facilitate rapid
screening, electronic data capture, and mobility within
the busy ED setting.The logistics of conducting screening in the ED re-
quire that the screening process be relatively brief and
minimally intrusive. Further, to minimize potential as-
sessment reactivity in the MSO group, substance-
related screening questions were to be kept at an abso-
lute minimum. A four-section screening instrument, the
Tobacco, Alcohol, and Drug (TAD) questionnaire, will
be used to capture the substances assessed. To
maximize confidentiality, the TAD will be completed by
the participants, who will enter the data directly using
the tablet PC unless the participant is not comfortable
with this technology, in which case the data may be
entered by the RA. The four sections, which can be
completed in 5–10 minutes, consist of (1) the 4-item
Heavy Smoking Index [31], a brief screen for nicotine
dependence that is administered first to minimize par-
ticipant discomfort with answering more sensitive ques-
tions about drug use; (2) the three consumption items
of the Alcohol Use Disorders Identification Test
(AUDIT-C) [32,33]; (3) the DAST-10 [34-36]; and (4),
for individuals scoring ≥3 on the DAST-10, three ques-
tions to determine primary substance of abuse, days of
use of the primary substance, and substance-relatedness
of the ED visit. The screen is considered positive if the
DAST-10 score is ≥ 3 and the individual reports past 30-
day use of the primary substance.
Participants who meet screening criteria based on the
TAD will be further screened for eligibility by the RA,
who will ask participants about (1) current engagement
in addiction treatment, (2) whether they reside more
than 50 miles from the follow-up location, (3) ability to
provide at least two locators, and (4) access to a phone.
These two prescreening forms (the TAD and eligibility)
will not include identifying information. Individuals who
are interested and eligible to participate will then
undergo the informed consent process. Patients who do
not meet inclusion criteria will receive no further inter-
vention, but the anonymous screening data will be kept
to allow comparison to those who do meet criteria.
Informed consent process
Patients will be provided with an IRB-approved
informed-consent form that will include a description of
all significant elements of the study. The consent form
will also include assurances of confidentiality and a
statement that participation is entirely voluntary, that
the decision to participate will in no way influence other
aspects of the patient’s treatment, and that the partici-
pant is free to withdraw participation at any time.
Patients must be able to read the first paragraph of the
informed consent and express verbally their under-
standing of the key elements of the study (e.g., random
assignment, possible interventions received, duration of
follow-up). They will then indicate their consent to
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informed consent form. A Health Insurance Portability
and Accountability Act (HIPAA) disclosure form will
also be required to allow the study to access protected
health information in the patient’s medical record in the
ED. Because of the time constraints of completing the
assessment and intervention in the ED, and because of
the relatively low risks associated with the study, the
consent form will be as brief as possible within the con-
straints of adequate human subject protections. Prior to
randomization, all consenting participants will complete
a demographic questionnaire, provide locator informa-
tion, and provide a hair sample, which will be used to
obtain an objective measure of substance use.
Randomization procedure
After providing informed consent, all eligible participants
will be randomly assigned in 1:1:1 ratio to one of the three
conditions (MSO, SAR, or BI-B). Randomization will be
stratified based on site, presence of an alcohol use dis-
order (AUDIT-C score ≥ 4), and drug problem severity
(DAST-10 score ≥ 8). The randomization procedure will
be conducted through a centralized, web-based process
set up by the NIDA Clinical Trials Network Data and
Statistics Center. The randomization sequence will be
unknown to staff, and treatment assignment will be
revealed in two stages. Initially, the RA performing the
randomization will be informed as to whether the par-
ticipant is in the MSO group or not. If so, the RA is fin-
ished with the research component in the ED and will
have no further study involvement until the 3-month
follow-up visit. The remaining participants will receive a
more extensive baseline assessment. After completion
of the baseline assessment, RAs will be informed
whether participants are in the SAR or BI-B group.
Research assistants conducting the follow-up assess-
ments will be blinded to treatment condition. The
randomization scheme was designed to balance patient
allocation to each treatment arm. Given the intent-to-
treat nature of the study, participant dropouts after
randomization will not be replaced.
Baseline assessments (SAR and BI-B groups only)
Given both the concerns about the potential effects
of assessment reactivity and the practical difficulties
associated with an extensive assessment procedure
(e.g., interfering with the rapid pace of clinical treatment
in the ED setting), the baseline assessment is shorter
than that often found in addiction treatment trials. The
semistructured 30-day TLFB interview [27,28] is the
measure from which the primary outcome will be
derived. The TLFB, which uses a calendar prompt and a
number of other memory aids to facilitate accurate re-
call, provides estimates of the daily quantity, frequency,and pattern of substance use (cannabis, cocaine, meth-
amphetamine and prescription stimulants, heroin and
prescription opioids, inhalants, sedatives, hallucinogens,
alcohol, tobacco, and other drugs) during a specified
time period. For each day of use, the RA also will record
both the number of times the substance was used and
the dollar value of the amount of substance consumed.
The baseline assessment also will include the NM-
ASSIST [29,37] to assess frequency of use and asso-
ciated problems for a number of substances including
tobacco, alcohol, cannabis, cocaine, amphetamine-type
stimulants, inhalants, sedatives, hallucinogens, opioids,
and other drugs. The NM-ASSIST includes a separate
assessment of prescription stimulants and metham-
phetamine and of prescription opioids and heroin. The
total time burden for the baseline assessment is ap-
proximately 30 minutes.
Hair testing will be used at baseline (following consent
and prior to assessments) and at 3-, 6-, and 12-month
follow-ups as an objective secondary measure of canna-
bis, cocaine, amphetamine, methamphetamine, opioid,
and benzodiazepine use. Compared with body fluids
such as urine or saliva, hair testing enables the detection
of substance use over a significantly longer window of
time [38,39] and is increasingly being used as an object-
ive approach complementary to self-reported substance
use outcomes in clinical trials. A significant benefit of
this testing approach is the comparatively nonintrusive
nature of collecting a hair sample from the scalp [40].
Study interventions
Minimal screening only (MSO)
Following randomization, participants in the MSO group
will receive an informational pamphlet about drug use
and its consequences, addiction, and treatment. This
pamphlet will consist of information collected from
materials produced by NIDA for the general public.
They will receive no further intervention.
Screening and referral (SAR)
Participants in the SAR group will receive the same in-
formational pamphlet as the MSO group. Those with
probable dependence (NM-ASSIST score ≥27 for any
drug or alcohol) will also be provided with minimal
scripted feedback to let them know their score is in the
high-risk range, and will receive a recommendation to
seek treatment. The RA will provide these participants
with an information sheet listing treatment and self-help
resources in their community. The latter will be standar-
dized in format but will include site-specific information,
i.e., names, addresses, and phone numbers of local
addiction treatment agencies in the normal clinical refer-
ral network of the participating EDs. Based on our initial
site survey, the majority of responding EDs are not
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SAR condition represents a level of care significantly
higher than treatment-as-usual.
Brief Intervention + booster (BI-B)
Individuals randomized to the BI-B condition will re-
ceive the same information and referral as those in SAR.
However, in addition to these materials, while in the ED
the BI-B group will receive a manual-guided BI based on
motivational interviewing (MI) principles, including
feedback based on screening information, the Feedback,
Responsibility, Advice, Menu of options, Empathy, Self-
efficacy (FRAMES) heuristic, and development of a
change plan, as delivered in previous trauma center trials
[6,41-44] and the Washington State SBIRT projects
[6,41,42,45-49]. As Sise [50] indicated, SBIRT services
such as these can be integrated effectively into all com-
ponents of a busy urban ED by adding specially trained
interventionists to the ED service staff and/or by train-
ing existing staff. The BI will be performed by study RAs
(rather than regular ED staff members) who have
received centralized training, have successfully com-
pleted and met criterion skill levels as assessed by ob-
jective ratings of tapes of their interventions with a
series of subsequent training cases, and who will receive
ongoing fidelity monitoring and clinical supervision over
the course of the trial. For a given study participant, BI
will be performed by a different RA than the one who
conducted assessments of that individual. The in-person
BI, which will be approximately 30 minutes long, will be
delivered while the participant is still in the ED. Partici-
pants in BI-B will receive the informational pamphlet
and referral for treatment (if indicated) from the BI
interventionist.
In addition, as a means of augmenting the intervention
in the ED, participants also will receive up to 2 phone
“booster” sessions. These sessions, which are also based
on MI principles, will check to see whether they have
engaged in treatment, review change plans, and seek a
commitment from them [51]. This number of booster
sessions was chosen to replicate the structure of the
standard Motivational Enhancement Therapy (MET)
[52], with the goal of maximizing the magnitude of the
therapeutic effect while keeping the intervention short
enough to be practical. The goal of the first phone ses-
sion is to re-engage and reinforce the change plan and
support continuing change efforts. The second phone
session is a check-in and addresses barriers to change or
treatment engagement. Each of these booster calls will
be approximately 20 minutes long. The content of these
boosters is patterned after sessions in MET [52,53]. The
phone booster process is similar to those previously used
to deal with problem drinkers in EDs, either as part of
stepped-care interventions initiated in the ED andcontinued following discharge [54] or as stand-alone
phone-delivered BIs conducted without an initial inter-
vention in the ED [51], and to procedures used in a pri-
mary care settings [55]. The target window for the initial
first and second phone booster calls is within 3 days and
within 7 days of discharge from the ED, respectively. If
initial attempts to complete the booster sessions within
these windows are unsuccessful, further attempts to en-
gage participants will be made for up to one month
post-discharge from the ED. Booster calls will be made
from a centralized, study-wide intervention booster call
center by interventionists who have received standar-
dized training and will have ongoing fidelity monitoring
and clinical supervision.
Follow-up assessments
Follow-up assessments will be conducted at 3, 6, and
12 months following the ED visit. In order to maintain
blinded follow-up, different RAs will be used to
complete baseline and follow-up assessments. If in-
person follow-up is not possible, follow-up visits may be
conducted by phone, but this should be avoided if pos-
sible, as hair samples would be missing in such cases. In
addition to measures of substance use (e.g., NM-ASSIST,
TLFB, hair sample), the Treatment Services Review
(TSR) [30] also will be administered at these follow-up
points to track substance-abuse treatment entry and
utilization and medical-treatment service utilization.
Follow-up will be conducted in person at a central lo-
cation, preferably close to the participating ED. Add-
itionally, if participants are unable to provide their own
transportation to or from follow-up visits, sites may pro-
vide transportation including bus or taxi fare if they have
local IRB approval to do so. As a means to achieve high
follow-up rates in the study population, adequate com-
pensation for time and inconvenience is critical. Com-
pensation of $50 for the screening/baseline visit and $75
for the 3-month visit (primary outcome) and subsequent
visits is proposed.
Safety assessment
Adverse events, serious adverse events, and substance
use events (e.g., worsening of drug use, need for higher
level of care, admission to detox or inpatient drug treat-
ment) will be monitored and reported throughout the
study. These events will be subject to ongoing monitor-
ing by the study executive committee and will be pre-
sented for review by the independent Data and Safety
Monitoring Board.
Blinding
As in almost all psychosocial treatment protocols, study
participants will not be blinded. However, because of the
two-stage method of revealing the randomized group
Table 1 Interpretation of potential assessment and
treatment effects based on outcomes of contrasts among
SMART-ED conditions
Equalities and Inequalities Conclusions
MSO* SAR** SAR/BI-B† Assessment Reactivity Treatment Effects
< < Yes Yes
< = Yes No
= < No Yes
= = No No
*MSO = minimal screen only. **SAR = screening, assessment, and referral to
treatment if indicated or requested. †SAR/BI-B = screening, assessment, and
referral if indicated or requested plus brief intervention and subsequent
telephone follow-up booster sessions.
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be partially blinded until the assessment has been com-
pleted. The RAs conducting follow-up assessments will
be different from those conducting the baseline assess-
ments and will be blinded to treatment condition. To
further minimize potential bias, the RA who conducts
the baseline assessment in the ED will not be the same
one that conducts the BI-B intervention with that
patient.
Sample size determination
There is no straightforward way to estimate the effect
size of the proposed contrasts across the three condi-
tions due to differences across critical aspects of prior
SBIRT studies (e.g., primary care setting rather than ED,
or alcohol versus drug use as the primary outcome).
While previously published studies guided our estimates
of treatment effect, the power analysis and sample size
calculations were based on the minimum clinically sig-
nificant nonstandardized effect that we wish to be able
to detect between SAR and BI-B, and estimates of error
variance based on the data collected in the Washington
State implementation of an SBIRT model in ED setting
[48,56]. In order to detect an absolute difference of three
days between the two groups, which was considered to
be a clinically meaningful difference, and with an esti-
mated standard deviation of 11 days, an anticipated 15%
attrition rate, and a Type I error α= .05/3 (two-tailed), a
total of 1285 subjects (429 in each arm) was determined
necessary to have 90% power. Estimating conservatively
that 5% of screened patients will meet inclusion criteria,
and that 75% of these will consent to participate in the
study, it will be necessary to screen 34,267 patients
(5711 per site) to achieve the proposed sample of 1285
randomized participants. We propose to screen approxi-
mately 160 individuals per week per site to achieve the
targeted enrollment rate of six participants per week per
site. This will allow recruitment at each site to be
accomplished within nine months.
Statistical methods for primary analyses
The primary analyses will consist of three prespecified
pair-wise comparisons between the MSO, SAR, and BI-B
conditions with respect to the primary outcome variable
(number of days of use of the primary drug of abuse in
the past 30 days at three-month follow-up based on the
TLFB), all of which will use a simple closed testing pro-
cedure to control family-wide Type I error at no more
than 0.05. Linear mixed-model analyses with a random
site effect and fixed treatment effect and intercept will
be used. These analyses will take into account possible
variability in the overall level of abstinence between the
sites, possible site-by-treatment interaction, and the level
of a baseline covariate (days of use of the primary drugof abuse, as defined at screening by the DAST-10, during
the 30 days preceding the baseline assessment). The pri-
mary outcome will be analyzed according to the intent-
to-treat principle. Patients who refuse treatment will still
be followed for outcome in their assigned group, but no
attempt will be made to impute outcomes for these
patients.
Potential interpretations of prespecified group
comparisons
The proposed design provides the opportunity to make
a number of meaningful comparisons. First, the con-
trast between the SAR and BI-B groups allows a deter-
mination of the incremental benefit of the assessment
+ BI + booster sessions over and above the effects of
the assessment alone. This contrast has been con-
ducted in most prior SBIRT studies and is the one for
which the group differences and effect size may be atte-
nuated due to potential assessment reactivity. The
second comparison, between the SAR and MSO, allows
the determination of any incremental therapeutic
effects of assessment over and above minimal contact.
This comparison provides the quantification of the as-
sessment reactivity effect. The final comparison, be-
tween the BI-B and MSO groups, provides a measure
of the total effect of the intervention, including any
therapeutic effects of assessment and referral. The
MSO condition actually offers a better approximation
of true treatment-as-usual, as opposed to SAR, since
the latter condition represents a greater intensity of
intervention than is typically found in EDs.
There are many potential equalities and inequalities that
can hold between the three arms of the SMART-ED
design. Assuming that abstinence is the outcome (and the
bigger the better), the most intuitive results of possible
comparisons and appropriate conclusions are depicted in
Table 1. For example, if MSO < SAR < BI-B, we may con-
clude that there is both assessment reactivity and a treat-
ment effect. Other rows can be interpreted similarly.
Thus, each significant difference, or lack of difference,
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presence or absence of assessment and/or treatment
effects but with different implications for practice.
While assessment has typically been an integral com-
ponent of BI, in a number of general health-care settings
it is likely that BI may be conducted without assessment;
there is often limited or no time for conducting an as-
sessment beyond a brief screen in such settings, and as-
sessment is often seen as complex by generalist
clinicians. The possibility and effectiveness of conduct-
ing BIs without assessment is a condition that is not
examined in the current design. Conversely, it is possible
to have assessment without treatment. If the SAR condi-
tion has a better outcome than the minimal screen only
(MSO) condition, and the BI-B condition does not out-
perform SAR, then a case could be made for simply con-
ducting an assessment and subsequent referral to
specialty substance abuse treatment. Given the added
costs involved, an intervention should be avoided if it
does not significantly add to the outcome over and
above that of SAR.
Discussion
While the three-arm design follows the recommendation
for taking potential assessment reactivity into account,
there are a number of limitations that need to be noted.
One obvious limitation is that the effects of the minimal
screening, which may not be negligible, cannot be
assessed [26]. A number of screening instruments that
have been developed for use in SBIRT trials consist of as
few as one item [57,58]. Although the MSO condition
attempts to minimize the length of the screening pro-
cedure and measure its impact, it nevertheless consists
of 20 items, including the 4-item Heavy Smoking Index
[59], the AUDIT-C [32], the DAST-10 [34], and the 3
questions on primary substance of abuse, days of use,
and substance-relatedness of the ED visit. A recent
meta-analysis and systematic review of BI [13] showed
that merely asking questions about alcohol use alters
subsequent drinking behavior even in the absence of a
more intensive assessment or intervention.
Second, another approach to reducing bias in SBIRT
trials may be to blind subjects to study purpose as a way
of limiting the potential effects of social desirability [15].
The SMART-ED design does not address this issue spe-
cifically; however, participants and staff are blinded to
final condition assignment via the two-step process of
revealing the randomization results. The RA who con-
ducts the screening and baseline assessment and who is
made aware of the randomized treatment assignment
“hands off” the patient to a different RA who delivers
the assigned intervention, thus minimizing the likelihood
that participants will be treated differently (e.g. subtly
advising MSO subjects to change). Further, research staffwho conduct follow-up assessments are different from
those who conduct baseline assessments or interventions
in the ED and are blind to participants’ treatment
condition.
Blinding subjects to study purpose is difficult given
both the need for informed consent and the nature and
content of the screening instrument. It is not possible to
determine what impact the consent process has on out-
comes given that, in the current trial (as in many similar
trials), the IRBs require disclosure of the purpose and
procedures of the study. The present study was granted
IRB approval to use an abbreviated script to approach
potential participants in the ED and ask if they would be
willing to answer the TAD screening question; only
verbal (not signed) consent was required. Even this pro-
cedure, however, alerts individuals to the intended focus
on substance use. The collection of hair samples follow-
ing completion of the screening questionnaire by all po-
tential subjects but prior to obtaining formal written
consent may alter individuals’ willingness to volunteer
for the study. Similarly, the collection of hair samples
following the screen but prior to the baseline assessment
for the SAR and BI-B groups might alter responses
across these two sets of drug-use data.
While research ethics need to be followed, methods to
increase the blinding of potential subjects in BI studies
have been approved by IRBs. As an example, patients in
a Level-I trauma center who screened positive for haz-
ardous or harmful alcohol use were asked to give con-
sent to assess their long-term outcome from trauma
[44]. Assessments included 6- and 12-month follow-up
interviews and review of their medical records and other
databases. Consent was not obtained for randomization
into an SBIRT intervention or control group, nor were
patients told they were taking part in a study to reduce
alcohol consumption. After consent, patients were ran-
domized to an intervention or control group. Such a
procedure avoided the bias that otherwise might have
occurred because more seriously alcohol-impaired or
dependent patients may have refused to participate, and
patients who did participate would have been sensitized
to the fact that their drinking would be monitored [15].
Finally, it is unclear to what extent the presence or ab-
sence of assessment reactivity in SMART-ED can be
generalized to other trials with other assessments.
Although there are questions about whether assess-
ment reactivity effects occur in BI studies in general
[11], and, more specifically, in those delivered in EDs
[23-25], it is important to use designs that take this pos-
sibility into account. As noted, a number of methodo-
logical factors may contribute to biases that can lead to
an underestimation of the impact of BI, and these factors
need to be minimized as much as possible. The design
of the SMART-ED study allows determination of the
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the change in subsequent substance use, although it is
not able to address or eliminate other sources of poten-
tial bias. The ability to disaggregate the effects attribut-
able to assessment versus the BI is methodologically
important and allows a clearer perspective of the mech-
anism of action in the observed change in alcohol or
drug use.
From both a clinical and public health perspective,
however, this methodological disaggregation of relative
effects may be less important. The SBIRT approach
has typically followed a stepped-care approach; some
form of screening, often asking as few as one question
[58], is used for case-finding purposes. In a number
of general health-care settings, a positive response to
such a screening item might be sufficient to lead dir-
ectly to BI and/or advice to change behavior without
conducting a more extended assessment. In other set-
tings, an assessment (even brief ) is conducted with
patients who score positive for problem substance use
to provide additional information about the nature
and severity of use beyond the initial screen, after
which a brief motivationally focused intervention is
conducted, usually incorporating feedback based on
information derived from the assessment. Assessment
is considered to be an integral component of the
intervention “bundle” in such an approach. Thus, if
integrated into the intervention, and if found to con-
tribute independently to the change process, assess-
ments could be designed to maximize the therapeutic
benefit they provide and add to the overall interven-
tion effectiveness [9].
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